Molecular pathology of lung cancer: clinical aspects
Discovery of tyrosine kinase inhibitor sensitizing mutations in lung cancer (LC) appears to be the main event in clinical oncology of the last decade. Activating lesions in epidermal growth factor receptor (EGFR) gene almost guarantee tumor response to gefitinib, erlotinib or afatinib.ALK translocat...
| Prif Awduron: | , |
|---|---|
| Fformat: | Erthygl |
| Iaith: | Russian |
| Cyhoeddwyd: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2016-02-01
|
| Cyfres: | Сибирский онкологический журнал |
| Pynciau: | |
| Mynediad Ar-lein: | https://www.siboncoj.ru/jour/article/view/255 |